Unlike Vascular Endothelial Growth Factor (VEGF) -inhibitors used intravitreally for treating exudative age-related macular degeneration, which have a short half-life in the eye of just a few days [35], no similar data exists for the anti-IL-6 antibody. Here, VEGFA is linked to age-related macular degeneration.